Molecular typing relies on molecular genetic tests and is not nonetheless routinely obtainable. Molecular subtypes and immunohistochemical surrogate markers of your tumors (HR, HER2, triple unfavorable) correlate in about 70%. The differentiation of luminal A and B subtypes by HR status and proliferation markers like Ki-67 could be valuable, https://bjorkj319fmt5.dgbloggers.com/profile